Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

Flex Pharma

Status and phase

Withdrawn

Phase 2

Phase 1

Conditions

Fasciculation

Amyotrophic Lateral Sclerosis

Treatments

Drug: FLX-787-ODT (orally disintigrating tablet)

Study type

Interventional

Funder types

Industry

Identifiers

NCT03338114

FLX-787-106

Details and patient eligibility

About

The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS). The study will measure how often fasciculations occur, and monitor any side effects that might develop while taking the investigational product. Participants will be assessed before and after taking a single dose of FLX-787-ODT. Approximately 15 people will take part in this study at one center in the United States. Participants will be in the study for a single clinic visit and receive a telephone call 7 days later to monitor for side effects.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Documented diagnosis of ALS diagnosis of less than 3 years.
Expected survival > 6 months
Frequent fasciculations noted during clinical examination of any single muscle (>6 visible fasciculations per minute) observed in Part I
Normal oral cavity exam at screening
Proficient in English
Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study
Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study

Exclusion criteria

Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results
Tremor or other movement disorder that would interfere with recording
Inability to lie flat
Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers
Presence of laryngospasm or significant swallowing problems
Presence of percutaneous endoscopic gastrostomy, esophagogastroduodenoscopy, or G-tube
Inability to tolerate a spicy sensation in the mouth or stomach
Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol
Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening
Pregnant, breastfeeding, or planning to become pregnant
Blood pressure of ≥160 mmHg systolic and/or ≥100 mmHg diastolic
Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).